Senseera
Senseera develops liquid biopsy blood tests for cancer diagnosis using its proprietary cfChIP-seq technology that detects cell-free chromatin tissue to identify patient-specific gene expression. Starting with just 1mL of plasma, the platform captures and sequences active chromatin, profiling over 1 million genomic features per sample to generate high-resolution gene expression biomarkers. Senseera's pipeline…
Funding snapshot
About
Senseera develops liquid biopsy blood tests for cancer diagnosis using its proprietary cfChIP-seq technology that detects cell-free chromatin tissue to identify patient-specific gene expression. Starting with just 1mL of plasma, the platform captures and sequences active chromatin, profiling over 1 million genomic features per sample to generate high-resolution gene expression biomarkers. Senseera's pipeline includes liver transplant rejection, MASH, and liver cancer diagnostics. Founded in 2020 and headquartered in Jerusalem, Israel, the company has raised approximately $7.1M in seed funding led by Lightspeed Venture Partners. Senseera differentiates itself through its AI-driven chromatin liquid biopsy platform that uncovers the molecular state of cells to inform disease biology and guide treatment decisions. The technology enables non-invasive insights across precision oncology, cell therapy, metabolic disease, and immune disease, enhancing every step of drug development from target selection to treatment monitoring.
Business model
Oncology > In-Vitro Diagnostic Tests > Gastrointestinal Cancer > Liver Cancer,
Transplant Medicine > In Vitro Diagnostic Tests,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy
Team background
College Wise > Technion Israel Institute Technology, Technion - Israel Institute of Technology
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.